Pier Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Pier Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-165,913	Closed	-$4.62M	–	128
2021 Q3	$4.62M	Sell	165,913 -4,403	-3%	-$126K	0.48%	96
2021 Q2	$5.05M	Buy	+170,316	New	+$4.91M	0.51%	93
2014 Q3	–	Sell	-106,985	Closed	-$3.64M	–	160
2014 Q2	$3.64M	Buy	+106,985	New	+$3.35M	0.52%	90

Other funds holding RVNC

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Pier Capital's RVNC Position: Q4 2021 in Review

Pier Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 165,913 shares — an estimated $4.62M sold.

Pier Capital first reported a position in RVNC in Q2 2014 and held it in 3 quarters. The position peaked at $5.05M in Q2 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

Pier Capital reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Pier Capital sold 165,913 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $4.62M.
Pier Capital first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
Pier Capital's Revance Therapeutics, Inc. position peaked at $5.05M in Q2 2021.
151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on Pier Capital's 13F filing for Q4 2021, filed 10 Feb 2022.